Similar articles

• [Urinary 5-S-cysteinyldopa in malignant melanoma subjects-with special reference to melanoma stages and dopa loading test (author's transl)].

  Ichihasi M, Mojamdar M, Mishima Y. Ichihasi M, et al. Nihon Hifuka Gakkai Zasshi. 1981 Sep;91(10):1045-9. Nihon Hifuka Gakkai Zasshi. 1981. PMID: 6798247 Japanese. No abstract available.
• Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.

  Morishima T, Tatsumi F, Fukada E, Saito M, Fujita M, Nagashima N, Hanawa S. Morishima T, et al. Arch Dermatol Res. 1983;275(2):76-9. doi: 10.1007/BF00412878. Arch Dermatol Res. 1983. PMID: 6409012
• Isolation of 2-S-cysteinyldopa and 2,5-S,S-dicysteinyldopa from the urine of patients with melanoma.

  Prota G, Rorsman H, Rosengren AM, Rosengren E. Prota G, et al. Experientia. 1977 Jun 15;33(6):720-1. doi: 10.1007/BF01944148. Experientia. 1977. PMID: 891724 No abstract available.
• [Therapeutic evaluation of human malignant melanoma by urinary 5-S-cysteinyldopa dynamics: chemotherapy and surgery].

  Inoi T, Mojamdar M, Ichihashi M, Mishima Y. Inoi T, et al. Nihon Hifuka Gakkai Zasshi. 1984 Jan;94(1):39-43. Nihon Hifuka Gakkai Zasshi. 1984. PMID: 6433083 Japanese. No abstract available.
• Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.

  Stewart RM, Miller S, Gunder M. Stewart RM, et al. Acta Derm Venereol. 1983;63(2):97-101. Acta Derm Venereol. 1983. PMID: 6189350